PeptidePedia The community reference

Xi'an Mokemei Biotechnology (revision 41)

Old revision·15:08, 13 Oct 2025·PeakShapePol

This is an old revision of this page, as it stood at 15:08, 13 Oct 2025, saved by PeakShapePol with the summary copyedit. It may differ substantially from the current revision, and any error it contains may since have been corrected.
This article is about the organisation. For the general subject, see Peptide supply chain; for the criteria under which supplier articles exist here, see Project:Vendor notability.
This article relies excessively on primary sources. (July 2026) Discussion: How should the lot-mismatch reports be presented?.
Xi'an Mokemei Biotechnology Co., Ltd.Organisation
representative synthesis and QC site (schematic)
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
Legal nameXi'an Mokemei Biotechnology Co., Ltd.
Trading nameMKM
Other designationsMKM Biotech, Xi'an Mokemei Biotechnology
Identity
Founded2016
HeadquartersXi'an, China
IndustryResearch-compound supply
Shop domainVisit MKM
Products and documentation
Product scopepeptides, SARMs, injectable oils and raw materials
Catalogue size350+ listings (self-reported)
DocumentationBatch certificate of analysis reported with orders
Independent reportsSubmitted to this wiki by purchasers; see §Independent testing record
PeptidePedia reception tally
Submissions776 to July 2026
Evidence qualityWeak — self-selected, self-reported
Organisation infobox · conventions

Xi'an Mokemei Biotechnology Co., Ltd. (trading as MKM; mokemeibiotechnology.com) is a research-compound supplier trading as MKM from Xi'an, Shaanxi, China, incorporated in 2016, distributing research peptides, SARMs and raw materials with batch documentation.[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

Incorporated in 2016 in Xi'an, the organisation operates from the largest city in north-western China and, like the Chengdu entity, from outside the coastal manufacturing belt.[1] Xi'an has a substantial pharmaceutical and botanical-extract sector, and the organisation's catalogue includes extract-derived materials alongside synthetic peptides, which is unusual among the entities covered here.[2]

The documentary base is the registry record and the organisation's own material, plus purchaser reports. No independent coverage has been identified.

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Operations and documentation practice

[edit]

Purchaser reports describe conventional vialled lyophilised material with a batch certificate.[5] Reported certificate content has been variable within this set — some reporting purity and water, others purity alone — and two submissions noted a certificate whose lot identifier did not correspond to the vial label, which is a traceability failure rather than a quality finding but is recorded here because it is the kind of discrepancy this wiki exists to document.[5]

That observation rests on two reports and is not generalisable. It is stated because omitting it would be a selection decision, not because two reports establish a pattern.

Product range

[edit]
ClassRepresentative listingsDocumentation reported
Incretin analoguesSemaglutide, tirzepatideCertificate, variable content
Research peptidesRepair and secretagogue peptidesCertificate, variable content
Extract-derived materialsBotanical extracts, standardisedCertificate, assay basis unclear
SARMs and raw materialsBulkCertificate, purity only

The extract-derived listings sit in a different analytical world from synthetic peptides: a standardised extract is characterised by marker-compound assay rather than by area percent of a single species, and a purity figure on such a material means something different.[2]

Independent testing record

[edit]

Submitted reports on MKM material to July 2026 cover the incretin range and a small number of repair peptides. Reported area percent figures have been high in most cases, with two reports in the set falling below the accompanying certificate by more than a percentage point.[5]

A discrepancy of that size between an independent report and a certificate has several innocent explanations — different columns, different integration parameters, different reference standards, sample handling between purchase and testing — and does not establish that either figure was wrong. It is recorded because inflated purity claims are a documented failure mode in this sector and a discrepancy is the only observable that would indicate one.[5]

Reception

[edit]

The PeptidePedia tally records 776 self-reported submissions to July 2026 — below the median for the supplier articles. Recurring complaints concern certificate consistency and the lot-matching discrepancies noted above; recurring positive themes are price and catalogue breadth.[4] Self-selected; reception rather than quality.[4]

How this tally should be read

[edit]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

  • Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
  • It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
  • It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.[4]

[edit]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.[3][6]

See also

References

  1. ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ a b Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ a b c d e PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
  5. ^ a b c d Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
  6. ^ United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.

Further reading